Download MendeleyDiscovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP).
Tamanini, E., Buck, I.M., Chessari, G., Chiarparin, E., Day, J.E.H., Frederickson, M., Griffiths-Jones, C.M., Hearn, K., Heightman, T.D., Iqbal, A., Johnson, C.N., Lewis, E.J., Martins, V., Peakman, T., Reader, M., Rich, S.J., Ward, G.A., Williams, P.A., Wilsher, N.E.(2017) J Med Chem 60: 4611-4625
- PubMed: 28492317
- DOI: https://doi.org/10.1021/acs.jmedchem.6b01877
- Primary Citation of Related Structures:
5M6E, 5M6F, 5M6H, 5M6L, 5M6M, 5M6N - PubMed Abstract:
XIAP and cIAP1 are members of the inhibitor of apoptosis protein (IAP) family and are key regulators of anti-apoptotic and pro-survival signaling pathways. Overexpression of IAPs occurs in various cancers and has been associated with tumor progression and resistance to treatment. Structure-based drug design (SBDD) guided by structural information from X-ray crystallography, computational studies, and NMR solution conformational analysis was successfully applied to a fragment-derived lead resulting in AT-IAP, a potent, orally bioavailable, dual antagonist of XIAP and cIAP1 and a structurally novel chemical probe for IAP biology.
Organizational Affiliation:
Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, U.K.
